Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations, and response to treatment

Rosalind L. Smyth; John P. Scott; Leszek K. Borysiewicz; Linda D. Sharples; Susan Stewart; Timothy G. Wreghitt; James J. Gray; Timothy W. Higenbottam; John Wallwork

doi:10.1093/infdis/164.6.1045

Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations, and response to treatment

Rosalind L. Smyth^*, John P. Scott, Leszek K. Borysiewicz, Linda D. Sharples, Susan Stewart, Timothy G. Wreghitt, James J. Gray, Timothy W. Higenbottam, John Wallwork

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

83 Citations (Scopus)

Abstract

The risk factors, clinical associations, and response to treatment of cytomegalovirus (CMV) pneumonia and infection were studied in 65 recipients of heart-lung transplantation. There were 29 episodes of CMV pneumonia in 22 patients. In 80% (20/25) of episodes of CMV pneumonia treated with intravenous ganciclovir, the histologic changes resolved and the patient survived. Among seronegative recipients, a seropositive donor was a significant risk factor for CMV pneumonia and infection in the first 90 days after heart-lung transplantation (P = .004 and .002, respectively). Among seropositive recipients, there was no additional risk associated with a seropositive donor. Rates of CMV pneumonia and infection were significantly increased when treatment with augmented immunosuppression had been given in the preceding 30 days (P < .001). A significant association was found between CMV pneumonia or infection and pulmonary bacterial infections occurring 30 days before or after such an episode (P < .001).

Original language	English
Pages (from-to)	1045-1050
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	164
Issue number	6
DOIs	https://doi.org/10.1093/infdis/164.6.1045
Publication status	Published - Dec 1991

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/164.6.1045

Cite this

Smyth, R. L., Scott, J. P., Borysiewicz, L. K., Sharples, L. D., Stewart, S., Wreghitt, T. G., Gray, J. J., Higenbottam, T. W., & Wallwork, J. (1991). Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations, and response to treatment. Journal of Infectious Diseases, 164(6), 1045-1050. https://doi.org/10.1093/infdis/164.6.1045

@article{da33a6fb28db48a89c41c9c1ef951a2d,

title = "Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations, and response to treatment",

abstract = "The risk factors, clinical associations, and response to treatment of cytomegalovirus (CMV) pneumonia and infection were studied in 65 recipients of heart-lung transplantation. There were 29 episodes of CMV pneumonia in 22 patients. In 80% (20/25) of episodes of CMV pneumonia treated with intravenous ganciclovir, the histologic changes resolved and the patient survived. Among seronegative recipients, a seropositive donor was a significant risk factor for CMV pneumonia and infection in the first 90 days after heart-lung transplantation (P = .004 and .002, respectively). Among seropositive recipients, there was no additional risk associated with a seropositive donor. Rates of CMV pneumonia and infection were significantly increased when treatment with augmented immunosuppression had been given in the preceding 30 days (P < .001). A significant association was found between CMV pneumonia or infection and pulmonary bacterial infections occurring 30 days before or after such an episode (P < .001).",

author = "Smyth, {Rosalind L.} and Scott, {John P.} and Borysiewicz, {Leszek K.} and Sharples, {Linda D.} and Susan Stewart and Wreghitt, {Timothy G.} and Gray, {James J.} and Higenbottam, {Timothy W.} and John Wallwork",

year = "1991",

month = dec,

doi = "10.1093/infdis/164.6.1045",

language = "English",

volume = "164",

pages = "1045--1050",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Cytomegalovirus infection in heart-lung transplant recipients

T2 - Risk factors, clinical associations, and response to treatment

AU - Smyth, Rosalind L.

AU - Scott, John P.

AU - Borysiewicz, Leszek K.

AU - Sharples, Linda D.

AU - Stewart, Susan

AU - Wreghitt, Timothy G.

AU - Gray, James J.

AU - Higenbottam, Timothy W.

AU - Wallwork, John

PY - 1991/12

Y1 - 1991/12

N2 - The risk factors, clinical associations, and response to treatment of cytomegalovirus (CMV) pneumonia and infection were studied in 65 recipients of heart-lung transplantation. There were 29 episodes of CMV pneumonia in 22 patients. In 80% (20/25) of episodes of CMV pneumonia treated with intravenous ganciclovir, the histologic changes resolved and the patient survived. Among seronegative recipients, a seropositive donor was a significant risk factor for CMV pneumonia and infection in the first 90 days after heart-lung transplantation (P = .004 and .002, respectively). Among seropositive recipients, there was no additional risk associated with a seropositive donor. Rates of CMV pneumonia and infection were significantly increased when treatment with augmented immunosuppression had been given in the preceding 30 days (P < .001). A significant association was found between CMV pneumonia or infection and pulmonary bacterial infections occurring 30 days before or after such an episode (P < .001).

AB - The risk factors, clinical associations, and response to treatment of cytomegalovirus (CMV) pneumonia and infection were studied in 65 recipients of heart-lung transplantation. There were 29 episodes of CMV pneumonia in 22 patients. In 80% (20/25) of episodes of CMV pneumonia treated with intravenous ganciclovir, the histologic changes resolved and the patient survived. Among seronegative recipients, a seropositive donor was a significant risk factor for CMV pneumonia and infection in the first 90 days after heart-lung transplantation (P = .004 and .002, respectively). Among seropositive recipients, there was no additional risk associated with a seropositive donor. Rates of CMV pneumonia and infection were significantly increased when treatment with augmented immunosuppression had been given in the preceding 30 days (P < .001). A significant association was found between CMV pneumonia or infection and pulmonary bacterial infections occurring 30 days before or after such an episode (P < .001).

UR - http://www.scopus.com/inward/record.url?scp=0025757384&partnerID=8YFLogxK

U2 - 10.1093/infdis/164.6.1045

DO - 10.1093/infdis/164.6.1045

M3 - Article

C2 - 1659595

AN - SCOPUS:0025757384

SN - 0022-1899

VL - 164

SP - 1045

EP - 1050

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 6

ER -

Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations, and response to treatment

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this